Guillaume Marquis-Gravel, Amanda Stebbins, Lisa M Wruck, Matthew T Roe, Mark B Effron, Bradley G Hammill, Jeff Whittle, Jeffrey J VanWormer, Holly R Robertson, Jacqueline D Alikhaani, Sunil Kripalani, Peter M Farrehi, Saket Girotra, Catherine P Benziger, Tamar S Polonsky, J Greg Merritt, Kamal Gupta, Thomas E McCormick, Kirk U Knowlton, Sandeep K Jain, Ajar Kochar, Russell L Rothman, Robert A Harrington, Adrian F Hernandez, W Schuyler Jones
BACKGROUND: In patients with atherosclerotic cardiovascular disease, increasing age is concurrently associated with higher risks of ischemic and bleeding events. The objectives are to determine the impact of aspirin dose on clinical outcomes according to age in atherosclerotic cardiovascular disease. METHODS AND RESULTS: In the ADAPTABLE (Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-Term Effectiveness) trial, patients with atherosclerotic cardiovascular disease were randomized to daily aspirin doses of 81 mg or 325 mg...
February 13, 2024: Journal of the American Heart Association